The clinical evaluation of the Kampo therapy for Meniere disease.

The clinical evaluation of the Kampo therapy for Meniere disease. - The Kampo therapy for Meniere disease.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011247

Enrollment

Registered

2013-09-01

Start date

2013-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

meniere disease

Interventions

Isosorbide 60ml-90ml, Adenosine triphosphate disodium hydrate 3g, Mecobalamin 1.5mg Adenosine triphosphate disodium hydrate 3g, Mecobalamin 1.5mg, Kampo medicine

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Definite meniere disesase, Atypical meniere disease(cochlear type)

Exclusion criteria

Exclusion criteria: Atypical meniere disease(vestibular type) The patient who has been treated with modern or kampo medicine within a month for meniere disease.

Design outcomes

Primary

Measure	Time frame
Pure-tone audiometry,The frequency of vertigo,Visual analogue scale	—

Secondary

Measure	Time frame
Clinical stratification of meniere disease,Short increment sensitivity index test,Test for gaze and positional nystagmus,caloric test,Dizziness handicap inventory,MOS Short- Form 36-Item Health Survey	—

Countries

Japan

Contacts

Public ContactTatsuya Ishige

Oriental Medicine Reserch Center Division of Kampo medicine

03-3444-6161

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026